LXRX Lexicon Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-08 13:05
Why LXRX matters now
Lexicon Pharmaceuticals, Inc. (LXRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.27 with -4.02% on the session and $1.01B in market capitalization; recent performance reads 1-month -5.63% and YTD +74.78%.
The latest financial table shown here is Q1 2026, with revenue of $21.1M, net income of $-1.0M, and EPS of $-0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.3%.
The latest indexable market news headline is "Here's Why You Should Add LXRX Stock to Your Portfolio Now" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $6.00; recent insider activity includes DEBBANE RAYMOND filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.97
P/S
12.82
EV/EBITDA
-52.32
DCF Value
$-9.42
FCF Yield
-4.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.1%
Operating Margin
-34.8%
Net Margin
-37.5%
ROE
-18.6%
ROA
-9.7%
ROIC
-9.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $21.1M | $-1.0M | $-0.00 |
| Q4 2025 | $5.5M | $-15.5M | $-0.04 |
| FY 2025 | $49.8M | $-50.3M | $-0.14 |
| Q3 2025 | $14.2M | $-12.8M | $-0.04 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.07
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.